Regulation of ovarian steroid biosynthesis by estrogen during proestrus in the rat.
Studies were performed to test the hypothesis that the rapid decline in estradiol (E2) levels on proestrus before ovulation was due to a reduction in androgen substrate for aromatase, and that this decline in androgen was regulated by an estrogen receptor-mediated mechanism. Aromatase activity, concentrations of E2, androstenedione (A), testosterone (T), and progesterone (P4) in follicular, corpora lutea, and ovarian homogenates as well as peripheral E2, A, P4, and LH were measured in cycling rats from 1400-2000 h on proestrus. These parameters were also recorded after the expected E2 surge in animals treated at 1900 h on diestrous day 2 with the antiestrogen keoxifene (20 mg/kg), with or without an ovulatory dose of PMSG at 1600 h on proestrus. In a second experiment, P-450-17 alpha-hydroxylase/C17,20-lyase (P-450(17 alpha] activity was measured in a group of control rats at 1500, 1700, and 1900 h. Aromatase activity remained unchanged, even though serum and ovarian E2 levels were reduced from peak values at 1500 h to basal values at 1800 h (P less than 0.01). Peripheral A as well as ovarian androgens (specifically follicular but not luteal) A and T were also reduced over this time period (P less than 0.01). Although total ovarian P4 remained unchanged, follicular levels rose from 1400-2000 h (P less than 0.01). These reductions in androgens and E2 levels coincided with a marked reduction in follicular P-450(17 alpha) activity. Treatment with keoxifene with or without PMSG prevented the fall in peripheral E2 and A and the increase in peripheral P4 seen in controls. Ovarian and follicular E2, A, and to a lesser extent T were also remained at values similar to those during the E2 surge. Follicular P4 was reduced by both treatments. Neither treatment had any effect on aromatase. These results indicate that the fall in peripheral and ovarian E2 levels before ovulation was due to a decline in aromatizable androgen, through an inhibition of follicular P-450(17 alpha) enzyme activity, which appears to be mediated by an estrogen receptor-regulated mechanism.
Banks
P K
PK
Department of Pharmacology and Experimental Therapeutics, University of Maryland, Baltimore 21202.
Meyer
K
K
Brodie
A M
AM
D000704:Analysis of Variance; D000735:Androstenedione / Q000097:blood / Q000378:metabolism; D000818:Animals; D001141:Aromatase / Q000378:metabolism*; D003338:Corpus Luteum / Q000378:metabolism; D004031:Diestrus / Q000187:drug effects; D004958:Estradiol / Q000097:blood; D004965:Estrogen Antagonists / Q000494:pharmacology*; D005260:Female; D006064:Gonadotropins, Equine / Q000494:pharmacology*; D007986:Luteinizing Hormone / Q000097:blood; D006080:Ovarian Follicle / Q000378:metabolism; D010053:Ovary / Q000187:drug effects / Q000502:physiology*; D010880:Piperidines / Q000494:pharmacology*; D011359:Proestrus / Q000187:drug effects*; D011374:Progesterone / Q000097:blood / Q000378:metabolism; D020849:Raloxifene Hydrochloride; D051381:Rats; D011919:Rats, Inbred Strains; D012016:Reference Values; D013256:Steroids / Q000096:biosynthesis*; D013739:Testosterone / Q000378:metabolism
D004965:Estrogen Antagonists; D006064:Gonadotropins, Equine; D010880:Piperidines; D013256:Steroids; D013739:Testosterone; D000735:Androstenedione; D020849:Raloxifene Hydrochloride; D011374:Progesterone; D004958:Estradiol; D007986:Luteinizing Hormone; D001141:Aromatase